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ABSTRACT
Extracellular vesicles (EVs) are small extracellular membrane vesicles that serve as important inter-
cellular signalling intermediaries in both malignant and non-malignant cells. For EVs formed by the
plasma membrane, their biogenesis is characterized by an increase in intracellular calcium followed
by successive membrane and cytoskeletal changes. EV production is significantly higher in malignant
cells relative to non-malignant cells and previous work suggests this is dependent on increased
calcium mobilization and activity of calpain. However, differences in calcium-signalling pathways in
the context of malignant and non-malignant EV biogenesis remain unexplored. Here, we demon-
strate vesiculation is greater in malignant MCF-7 cells relative to non-malignant hCMEC-D3 cells,
increases in free cytosolic Ca2+ via endoplasmic reticulum (ER) Ca2+ store depletion with thapsigargin
increases EV biogenesis in both cell types, and vesicular induction is abolished by the intracellular Ca2
+ chelator BAPTA-AM. Store-operated calcium entry (SOCE) plays an essential role in the maintenance
of EV biogenesis after store depletion. These findings contribute to furthering our understanding of
extracellular vesicle biogenesis. Furthermore, since EVs are key mediators in the intercellular transfer
of deleterious cancer traits such as cancer multidrug resistance (MDR), understanding the molecular
mechanisms governing their biogenesis in cancer is the crucial first step in finding novel therapeutic
targets that circumvent EV-mediated MDR.
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Extracellular vesicles (EVs) are sub-micron sized mem-
brane-enclosed vesicles released from all cell types [1,2].
Released by all cell types, EVs as signalling vectors, reg-
ulate numerous physiological pathways ranging from
ageing to inflammation, coagulation to immunity. EVs
are also implicated inmediatingmany disease pathologies
including but not limited to; autoimmune disease, infec-
tious disease, cardiovascular disease and cancer. Of parti-
cular interest to our laboratory is their contribution to
cancer survival via promotion of metastasis, and che-
motherapeutic resistance. Tumour EVs mediate the
transfer of functional resistance proteins and nucleic
acids from drug-resistant to drug-sensitive cells resulting
in intercellular conferral of multidrug resistance (MDR)
[3–5]. We also showed through the study of EVs that
MDR was complex and extending beyond drug – cell
interactions. Specifically, EVs fromMDR cells could con-
fer increased metastatic capacity [6], active and passive
drug sequestration [7], immune evasion [8] and altered
tissue biomechanics [9].
The significance of EVs is not restricted to cellular
signalling and they have emerged as novel drug-
delivery vehicles, and important biomarkers [10,11].
Delineation of extracellular vesicle subtypes is typi-
cally based on size and biogenic origin [12,13]. The
cellular machinery and signalling pathways involved in
EV release also differ between EV subtypes. The pro-
cess for exosome biogenesis has been extensively
described by, Raposo and Stoorvogel [1], Colombo
et al. [14] and Kalra et al. [15]. In contrast, the biogen-
esis of plasma membrane-derived EVs is less well
defined, owing in part to early reports defining MVs
as simply inert by-products of cellular stress and/or cell
death [2,16–18].
Plasma membrane EV release can be initiated
through cellular activation in response to stimuli such
as exposure to serine proteases, thrombin, calcium
ionophores, ADP, inflammatory cytokines, growth fac-
tors and shear inducers [19–23]. In breast cancer cells,
the calcium channel TRPC5 is important in MDR via
extracellular vesicles [24]. Cellular activation and
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a subsequent increase in intracellular Ca2+ affects both
plasma membrane and cytosolic machinery leading to
plasma membrane EV biogenesis. At steady state,
phospholipids present in the plasma membrane are
asymmetrically distributed. The anionic phospholipids
phosphatidylserine (PS) and phosphatidylethanolamine
(PE) localize to the inner leaflet whilst phosphatidyl-
choline (PC) and sphingomyelin (SM) localize to the
outer [25]. A network of lipid translocases, modulated
by calcium, maintains the asymmetry [26–28]. Increase
in intracellular calcium results in the collapse of plasma
membrane phospholipid asymmetry resulting in
a destabilization of plasma membrane-cytoskeletal
anchorage [29,30]. Calcium mobilization concurrently
activates calpain, a cysteine protease, which in turn
cleaves several cytoskeletal components including
actin, ankyrin, protein 4.1 and spectrin [31,32].
Calpain-mediated cleavage of the cytoskeleton further
disrupts attachment to the membrane and these loca-
lized regions bud outwards to form plasma membrane
EVs [20,33,34].
An increase in intracellular calcium appears to be the
initiating step in plasma membrane EV biogenesis
[20,35–37].
The calcium ion (Ca2+) is a promiscuous signalling
molecule, involved in diverse cellular processes ranging
from neurological transmission to muscular contraction
[38]. In non-excitable cells, cellular calcium activates
signalling cascades through effects on Ca2+-regulated
proteins and also via Ca2+ dependent transcription fac-
tors [39].
Cells maintain tight control of compartmental Ca2+
homoeostasis through a network of calcium channels,
pumps and exchangers. This network facilitates simul-
taneous operation of calcium signalling pathways in
cells. Dysregulation of Ca2+ signalling is a key feature
of many diseases with calcium modulation forming
a significant part of pharmacotherapy [40–43].
In the context of malignancy, dysregulation of Ca2+
homoeostasis significantly contributes to disease progres-
sion [44] as well as facilitating other cancer hallmarks
[43,45]. For this reason, the therapeutic targeting of cal-
cium signalling presents clinical opportunities [40,46].
Despite the known relationship between elevated intra-
cellular calcium and plasma membrane vesiculation, the
exact pathway(s) and channels involved in biogenesis
remain to be fully defined.
We recently reported the presence of distinct vesi-
culation pathways in malignant and non-malignant
cells at rest [47]. We demonstrated that a calcium–
calpain dependent pathway regulated malignant cell
biogenesis and an alternative pathway driving biogen-
esis was proposed for non-malignant cells at rest [47].
In this paper, we investigate the Ca2+ signalling
pathways involved in regulating plasma membrane
EV biogenesis in malignant and non-malignant cells.
Specifically, we propose a role for endoplasmic reticu-
lum (ER) calcium stores and store-operated Ca2+ entry
(SOCE) in EV biogenesis. The discovery of discrete
pathways of biogenesis in malignant and non-
malignant cells is promising in the search for new
strategies to circumvent the acquisition and transfer
of plasma membrane EV-mediated deleterious traits
in cancer and for advancing knowledge in EV biology.
Methods
Cell culture
The drug-sensitive human breast adenocarcinoma cell
line MCF-7 and its drug-resistant sub-line MCF-7/Dx
(Dx for simplicity) were routinely cultured in RPMI-
1640 (Sigma-Aldrich, NSW, Australia) supplemented
with 10% FBS as previously described [48].
Incremental exposure of MCF-7 cells to doxorubicin
was used to develop the Dx resistant sub-line as pre-
viously described [48–50]. The non-malignant human
brain endothelial cell line (hCMEC-D3) was cultured
in Endothelial Cell Basal Medium-2 (EBM-2; Lonza,
MD, USA) as previously described [51]. All cell lines
were maintained at 37°C in a humidified 5% CO2
incubator. All cell lines were routinely tested for myco-
plasma infection.
Atomic force microscopy
The NanoWizard 4 BioScience Atomic Force
Microscope (AFM; JPK Instruments, Germany) was
used for cell surface topography studies. Cells were
fixed in 4% paraformaldehyde (PFA) for 30 min,
washed once with phosphate-buffered saline (PBS)
and twice with distilled water. Cells were air-dried for
~1 h to allow the membrane-bound vesicles to trans-
form to vesicle-derived pits as previously described
[47]. Topographical AFM imaging was carried out in
contact mode with sharpened silicon nitride cantilevers
(L: 225 µm, W: 46 µm, T: 1.0 µm, SPM Probe Model:
SHOCON; AppNano) with a tip radius of < 10 nm and
spring constant of 0.6 N/m. Scans were performed in
air at a rate of 1 Hz. Three areas were selected at
random for scanning for each treatment condition
and all experiments were performed in triplicate.
The raw data from AFM height measurements were
digitally filtered as previously described by Antonio
et al. [52] and Root Mean Square Roughness (RRMS)
was computed with the open source software
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Gwyddion [53]. The filtration procedure isolated fea-
tures of interest (plasma membrane EV-derived pits)
from features such as the overall cell shape. Given the
size range of plasma membrane EVs, the specific filtra-
tion procedure applied in this case is separating fea-
tures ranging from 100 to 1000 nm.
Each AFM image (30 µm2) was scanned with 512
points (scan step Δx = 58.6 nm) and a filtration pro-
cedure was applied with a cut-off normalized frequency
(fc) of 0.07 to remove all features with steps λ longer
than 1674.3 nm (λ = 2· Δx/fc). Previous work has
demonstrated that plasma membrane vesiculation in
occurs in perinuclear regions of the membrane [47].
Therefore, a “zoomed” 10 µm2 area was scanned within
each 30 µm2 was also taken to determine roughness in
these areas of surface. These scans consist of 512 points
(scan step Δx = 19.5 nm) and are filtered to remove
features larger than 975 nm (fc = 0.04; λ = 2· Δx/fc).
The Root Mean Square Roughness (RRMS) was then
computed as a quantitative measure of surface topo-
graphy across different treatments.
Intracellular calcium imaging and quantification in
MCF-7 cells using imageXpress
Cellular calcium was analysed using the ratiometric
fluorescent indicator, Fura-2 AM as previously
described [54,55]. Cells were loaded with Fura-2 AM
for 30 min at 37°C in the dark with a dye-loading
solution comprising 4 µM Fura-2 AM (Invitrogen) in
Dulbecco’s modified Eagle’s medium supplemented
with 10% foetal bovine serum with and without
50 μM 1,2-Bis(2-aminophenoxy)ethane-N,N,N′,N′-
tetraacetic acid tetrakis(acetoxymethyl ester) (BAPTA-
AM). Cells were allowed to incubate for a further
15 min in the dark at ambient temperature in physio-
logical salt solution (PSS [nominal]; 10 mM HEPES,
5.9 mM KCl, 1.4 mM MgCl2, 1.2 mM NaH2PO4,
5 mM NaHCO3, 140 mM NaCl, 11.5 mM glucose,
1.8 mM CaCl2, pH 7.3). Loading-dye solution was
removed and cells were washed twice with PSS Ca2+
(PSS supplemented with 1.8 mM CaCl2) and then twice
with PSS no added extracellular (nominal) to ensure
less than 100 µM Ca2+ was remaining in the test wells
[56]. Fresh PSS containing 1.8 mM CaCl2 was added
for intracellular calcium measurements.
MCF-7 cells loaded with Fura-2 AM were stimulated
with the sarco-endoplasmic reticulum calcium ATPase
(SERCA) inhibitor, thapsigargin (TG) (300 nM).
Experiments were performed using the
ImageXpressMICRO high content imaging system
(Molecular Devices, Sunnyvale, CA, USA).
Measurements were taken at an excitation wavelength
of 340 and 387 nm with fluorescence emission detected
using a 510–520 nm band pass filter. Two baseline
measurements were taken at 0 and 10 s. TG was loaded
into the reagent plate and added to test wells at 20 s.
Fura-2 AM ratio data points were acquired every 5 s
for a 300 s window. Relative changes in intracellular
calcium [Ca2+]I were determined following background
subtraction using the ratio of the two wavelengths, 340
and 387 nm for each time interval.
Cell viability following TG treatment
The effects of TG concentrations (1–300 nM) over
a 10 min treatment window on cell viability were
assessed by trypan blue dye exclusion at 24-h post
treatment as described [20].
MV isolation and quantitative flow cytometric
analysis of plasma membrane EVs
Plasma membrane EVs were isolated by a process of
differential centrifugation as previously described
[3,48]. Briefly, cell supernatants were collected from
approximately 1.2 × 107 cells and centrifuged for
5 min at 500 × g to remove cells and large cellular
debris. Smaller debris was removed by two further
spins at 2000 × g for 1 min. The supernatant was
collected and centrifuged at 18,000 × g for 30 min at
4°C to pellet EVs. Isolated EVs were resuspended in
200 µL PBS for analysis.
Flow cytometric analysis was conducted on the BD
LSRFortessa™ X-20 flow cytometer (BD Biosciences)
custom built with a 100 mW blue laser for small
particle detection. Plasma membrane EV gates were
established as previously described using latex sizing
beads 0.3–1.1 µm in diameter (BD Biosciences). The
threshold in side scatter was adjusted to 200 arbitrary
units to avoid background noise [57]. The predefined
gate was applied to all samples during analysis. The
performance of lasers was validated before each experi-
ment using BD FACSDiva™ CS&T Research Beads (BD,
Australia/New Zealand).
EV samples resuspended in PBS were combined
with TruCount™ beads and analysed according to
the manufacturer’s instructions. The tube was gently
vortexed and loaded onto the flow cytometer, after
which the fluid stream was allowed to stabilize to
a flow rate of 10 events/second for 30 s. To prevent
cross-contamination of samples, the sample line was
flushed with MilliQ water for at least 30 s between
each run. The stop gate was set at a fixed number of
2000 of Trucount™ beads during data acquisition.
A PBS blank buffer control was run to ensure
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baseline events were low (data not shown). The num-
ber of EVs per µL was calculated using the formula:
N = (gated MV events/gated Trucount™ events) ×
total number of Trucount™ beads [11]. EV events
were normalized to individual well cell counts to
account for variation in cell numbers between sam-
ples as previously described [20]. FACSDiva version
8.0.1 (BD Biosciences) was used for analysis of flow
cytometry data. Full description of methodologies
was also submitted to EV-TRACK (ID: EV190073)
Statistics and data analysis
Data were analysed with a one-way analysis of variance
(ANOVA) followed by a Dunnett’s multiple compar-
isons test using the GraphPad Prism version 7.02 for
Windows (GraphPad Software, La Jolla, CA, USA).
Data are presented as the mean or mean ± SD of 3
individual experiments with predictive results value of
(****) P < 0.0001, (***) P < 0.0005, (**) P < 0.01 and (*)
P < 0.05 were considered statistically significant.
Results
Mobilization of intracellular Ca2+ increases
vesiculation
Using pharmacological modulators of Ca2+ release
together with topographical AFM analysis we show
that intracellular calcium mobilization is required for
plasma membrane EV biogenesis. The Ca2+ ionophore,
A23187 (1 µM) was used to study the effect of increas-
ing intracellular Ca2+ on malignant (MCF-7 and Dx)
cell and non-malignant (hCMEC-D3) cell vesiculation
(Figure 1). Ca2+ ionophores mobilize Ca2+ through the
translocation of Ca2+-ionophore complexes across the
plasma membrane, activation of native plasma mem-
brane Ca2+ channels, and via mobilization of Ca2+ from
the ER [58].
Asmembrane-bound EVs are characteristically soft and
deformable when undergoing AFM imaging, we used an
indirect method for their examination whereby fixed cells
are air-dried and membrane vesicles are transformed into
vesicle-derived pits [47,59]. Prior to treatment with the
ionophore, hCMEC-D3 cells displayed a smooth surface
topographywith little to no vesiculation at rest (Figure 1(a),
left panel). Contrary to this, both malignant cell types,
displayed an abundance of vesicle-derived pits on the cell
surface at rest (Figure 1(b,c), left panels).
Increasing intracellular Ca2+ following A23187 treat-
ment resulted in a pronounced and modest increase in
vesiculation in non-malignant and malignant cells, respec-
tively. Non-malignant cells underwent a pronounced
change in topography with numerous vesicle-derived pits
observed following treatment with A23187 (Figure 1(a),
centre panel). In contrast, the increase in vesicle-derived
pits observed in malignant cells treated with A23187 was
less pronounced (Figure 1(b,c), centre panels). This is
consistent with our previous findings [47]. Both cell types
when treated with the calcium ionophore A23187 in com-
bination with the calcium chelator, BAPTA-AM (µM),
exhibited a smooth surface morphology devoid of vesicle-
derived pits (Figure 1(a, b and c) right panels). Together
these results evidence the involvement of intracellular Ca2+
mobilization in plasmamembrane EV vesiculation in both
malignant and non-malignant cells. Notably, the effects on
vesiculation following Ca2+ activation were less in malig-
nant cells compared with non-malignant cells and this is
likely due to the already elevated baseline Ca2+ activation
in MCF-7 cells at rest [60].
Increasing intracellular Ca2+ via store-operated Ca2+
entry (SOCE) activates EV vesiculation
The ER is the major intracellular store of calcium and is
maintained at higher Ca2+ concentrations (100–800 µM)
than that of the cytoplasm through the activity of Sarco/
endoplasmic reticulum calcium ATPase (SERCA)
[61,62]. We used Thapsigargin (TG) to selectively inhibit
SERCA, deplete the ER Ca2+ stores and in turn activate
SOCE [63]. Measurement of intracellular Ca2+ transients
were carried out using the ImageXpressMICRO high con-
tent imaging system as described by [64]. As shown in
Figure 2(a) treatment with TG resulted in a gradual
increase in relative [Ca2+]i over a 5 min measurement
interval. This corresponded to a significant increase in the
F340/F387 ratio – indicative of an increase in intracellular
[Ca2+]i (Figure 2(b)). The pre-treatment of cells with the
intracellular Ca2+ chelator, BAPTA-AM, (50 µM) abol-
ished the TG-induced increase in [Ca2+]i (Figure 2(a,b)).
AFM was used to visualize the effects of TG induced
[Ca2+]i increase on EV vesiculation in malignant and
non-malignant cells. MCF-7 and hCMEC-D3 cells were
treated with TG and the degree of vesiculation assessed
for 30 min post treatment. As shown in Figure 2(c)
(upper panels), non-malignant hCMEC-D3 cells dis-
play a smooth cellular topography supporting the pre-
sence of little to no vesiculation at rest. hCMEC-D3
cells treated for 5−30 min with TG displayed an uneven
surface topography with a significant increase in Root
Mean Squared (RMS) roughness (Figure 2(d)). This
change in surface roughness was accompanied by the
presence of vesicular pits, predominantly at perinuclear
regions. hCMEC-D3 cells treated with TG for
10–30 min induced numerous vesicle-derived pits
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localized in the perinuclear region, consistent with the
presence of active vesiculation (Figure 2).
Conversely, the malignant MCF-7 cells are observed
to have numerous vesicle derived pits compared to their
non-malignant counterparts (Figure 2(c) (lower panels)).
This supports these cells to be actively vesiculating at
rest, consistent with earlier studies by us [20,47]. Again,
there was a modest change in the surface topography
following treatment with TG over 30 min in MCF-7 cells
following TG treatment (Figure 2(c,d)). These studies
demonstrate an increase in vesiculation following TG
induced intracellular Ca2+ mobilization, particularly pro-
nounced in the non-malignant cells.
Pre-treatment with the intracellular calcium chela-
tor, BAPTA-AM effectively inhibited TG-induced vesi-
culation in both malignant and non-malignant cells
(Figure 3(a)). Together, these results establish a role
for [Ca2+]i in vesiculation in malignant and non-
malignant cells.
The high potency and irreversible binding of TG to
SERCAmeans that it can impact cell viability [65,66]. The
effects of TG on the viability of hCMEC-D3 and MCF-7
cells were assessed over 24 h using a Trypan Blue
Exclusion Assay to ensure viability under experimental
conditions. As shown in Figure 3(a,b), 10 nM TG treat-
ment for 5 min resulted in an observable increase in
vesiculation, whilst not affecting cell viability. This con-
centration was chosen for further investigations.
Flow cytometry was used to interrogate the Ca2+ signal-
ling pathways regulating plasmamembrane EV biogenesis.
The gating parameters for the EV region were defined
using 0.3 µm latex beads (R1: the lowest possible limit on
forward scatter for BD LSRII) and 1.1 µm beads (R2:
represents the upper limit for quantitation of the EV popu-
lation; Figure 4(a)), as previously described [11]. We
observed a significant, 1.5 fold increase in EV biogenesis
in hCMEC-D3 cells following 300 nM TG treatment
(Figure 4(b)). Resting hCMEC-D3 cells treated with the
Figure 1. AFM topographical images of vesiculation following increased intracellular calcium in malignant and non-malignant cells.
(a) hCMEC-D3, (b) MCF-7, and (c) Dx cells were imaged using AFM in contact mode (scan rate 1 Hz) in the presence and absence of treatment with
the calcium ionophore A23187 (1 µM) ± BAPTA-AM (50 µM) for 18 h. Ca2+ activation with A23187 resulted in increased vesiculation in all cells;
however, the effect is most prominent in non-malignant cells. The calcium chelator, BAPTA-AM inhibited the formation of EVs in all cells types.
Zoomed images shown in focussed panels as shown in frame. Scale bar shown. Image representative of a typical field of view from three
independent experiments.
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calpain inhibitor, ALLM (10 µM), displayed a 1.14 fold
increase in EV production (Figure 4(b)) consistent with
our previous findings [47]. This suggests to us that at rest
vesiculation is driven by a calpain-independent pathway in
non-malignant HCEM-D3 cells. Pre-treatment of
hCMEC-D3 cells with ALLM inhibited the TG-induced
plasma membrane EV production consistent with the
involvement of a calpain-dependent pathway driving vesi-
culation following TG treatment. Conversely, the addition
of the calpain inhibitor, ALLM to resting MCF-7 cells
significantly reduced EV production by 1.4 fold, consistent
with the involvement of calpain in EV vesiculation of
malignant MCF-7 cells at rest. ALLM also significantly
inhibited vesiculation by 2 fold in TG-treated MCF-7
Figure 2. Increasing intracellular calcium with thapsigargin (TG) induces plasma membrane EV biogenesis in malignant MCF-7 cells.
MCF-7 cells were treated with TG (300 nM) for 5 min in the presence and absence of BAPTA-AM (50 uM). Changes to intracellular calcium was
analysed using the ImageXpress high content imaging system and ratiometric calcium indicator Fura-2 AM. (a) Representative trace of change in
relative fluorescence of Fura-2 AM following treatment with TG alone (●) and in the presence of BAPTA-AM (▴) in MCF-7 cells. The rise in
fluorescence indicates increasing intracellular Ca2+ over 5 min. (b) Total TG-mediated increase in intracellular Ca2+ ± BAPTA-AM indicated by
increase in relative fluorescence of Fura-2 AM (340/387) in MCF-7 cells. Data represents the mean ± SD of three experiments. ***p < 0.001 (paired
t test). (c) Time course of TG-mediated increase in plasma membrane EV biogenesis. hCMEC-D3 (upper panel) and MCF-7 (lower panel) cells treated
for 5, 10, and 30 min with TG and EV-derived pits visualized with AFM (arrows). (d) Analysis of hCMEC-D3 and MCF-7 cell topography illustrates
there is an increase in surface roughness following thapsigargin treatment. Representative images shown from at least 3 experiments. Data
represent the mean ± SD of at least 3 experiments. *p < 0.05, **p < 0.005 (one way ANOVA).
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cells, with the effect on EV vesiculation being greater than
ALLM alone (Figure 4(b)).
YM58483 (N-[4-[3,5-Bis(trifluoromethyl)-1 H-pyrazol-
1-yl]phenyl]-4-methyl-1,2,3-thiadiazole-5-carboxamide) is
a selective inhibitor of SOCE and acts by blocking plasma
membrane Ca2+ channels which are activated upon ER
store depletion [67]. We observed no significant difference
in vesiculation in hCMEC-D3 cells treated with 1 µM
YM58483 alone compared to untreated control (Figure
4). Inhibition of TG activated SOCE with YM58483
resulted in a 1.5 fold decrease in vesiculation in hCMEC-
D3 cells compared to cells treated with TG. This effect was
also seen in malignant MCF-7 cells. Collectively, this data
suggests that depletion of internal calcium stores by TG
induced MVs in both hCMEC-D3 and MCF-7 cells and
demonstrates that ER-mediated calcium regulation pri-
marily drives vesiculation in malignant and non-
malignant cells. Consistent with this, the lack of reduction
in vesiculation of MCF-7 cells by the SOCE blocker
YM58483 alone, suggests that elevated basal EVs in
MCF-7 cells occurs through a pathway independent of
SOCE.
Taken together, these results establish a role for ER
Ca2+ as well as SOCE in the biogenesis of plasma
membrane EVs in malignant and non-malignant cells.
Non-malignant hCMEC-D3 cells are low vesiculators
at rest and display a large increase in vesiculation
following ER Ca2+ store depletion and activation of
SOCE. Contrary to this, malignant MCF-7 cells are
actively vesiculating at rest, and although SOCE can
contribute to MVs, SOCE is not the driver of increased
EVs in resting MCF-7 cells.
Discussion
An elevated intracellular Ca2+ is required in the bio-
genesis of microvesicles [35–37,47]. Despite the central
role that Ca2+ plays in plasma membrane EV biogen-
esis, the source of Ca2+ mobilization – intra- or extra-
cellular – driving plasma membrane vesiculation
remains undefined. We have previously shown that
distinct EV biogenic pathways exist between malignant
and non-malignant cells, the differences of which
appear related to intracellular calcium levels at rest
[47]. Uncovering the mechanistic differences between
malignant and non-malignant plasma membrane EV
biogenesis is important as it could point to novel and
selective treatment strategies for the circumvention of
MV-mediated acquisition and dissemination of MDR
Figure 3. Effects of Thapsigargin (TG)-induced microvesicle (MV) biogenesis on cell viability over 24 h.
hCMEC-D3 and MCF-7 cells were treated with TG (1–300 nM) for up to 10 min. Cells were washed and then incubated for a further 24 h and
analysed for viability and plasma membrane EV biogenesis. (a) AFM topographical images following TG (10 nM) treatment for 5 min ± BAPTA-AM
(50 µM). hCMEC-D3 (upper panels) and MCF-7 (lower panels). Images representative of three independent experiments. (b) hCMEC-D3 (upper
panel) and MCF-7 (lower panel) cell viability was assessed using a Trypan Blue dye Exclusion assay. Cells were treated with 1, 10 and 300 nM TG for
1 min (▴), 5 min (∎), and 10 min (●), washed and analysed 24 h post treatment. Data represent the mean ± SD of three experiments.
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and other deleterious traits in cancer cell populations.
This study sought to identify the calcium signalling
pathways involved in the vesiculation of malignant
MCF-7 and non-malignant hCMEC-D3 cells. We evi-
dence the involvement of the ER and SOCE pathway in
malignant and non-malignant plasma membrane EV
biogenesis. Malignant cells are high vesiculators at rest
compared to non-malignant cells, however, observed
differences do not appear to be related to mobilization
of Ca2+ following SOCE activation. SOCE does play
a role in plasma membrane EV biogenesis; however, it
serves as a failsafe mechanism – driving vesiculation in
the event ER stores are depleted of Ca2+.
At rest, non-malignant hCMEC-D3 cells are low
vesiculators and increases in intracellular Ca2+ result
in the induction of plasma membrane EV production.
Consistent with our previous work, high-resolution
AFM images show hCMEC-D3 cells have a smooth
topography with very few vesicle-derived pits observa-
ble in their resting state (Figure 1(a)). Following cellu-
lar activation with the Ca2+ ionophore, A23187, plasma
membrane vesicle biogenesis is efficiently “turned on”
in non-malignant cells. A23187 has been shown pre-
viously to elevate [Ca2+]i and induce plasma membrane
EV formation in a number of cell types [58] and these
results are consistent with this. Non-malignant cells
stimulated with A23187 displayed a dramatically
altered surface morphology consistent with cells under-
going active membrane vesiculation.
During plasma membrane EV biogenesis, the
increase in intracellular Ca2+ triggers a number of
cytoplasmic and membrane alterations including:
externalization of PS through the activation of lipid
translocases, loss of membrane asymmetry, activation
of calpain and the remodelling of the cytoskeleton.
Ultimately, anchorage of the plasma membrane to the
Figure 4. Vesiculation in malignant and non-malignant cells following manipulation of the calcium-calpain plasma membrane EV
biogenic pathway.
hCMEC-D3 and MCF-7 cells were treated with modulators of vesiculation and Ca2+ for 24 h EV release was quantified by flow cytometry. (a) EV size
gating strategy. Latex sizing beads of (0.3–1.1 um diameter) were used to define the gate for EVs. R1 represents the lower (0.3 µm) and R2
represents the upper (1.1 µm) limits set by the beads. R3 defines the region that was used to quantitate EVs and was applied to all samples. The
total number of acquired events when the stop gate was set at 5000 TruCount bead counts is shown on the right. Data are expressed as fold
change of EV release relative to vehicle control. (b) Non-malignant hCMEC-D3 cells displayed a significant increase in vesiculation following
thapsigargin (TG) treatment and a significant reduction in vesiculation when treated with TG and YM58483. While treatments produced
a consistent, small increase in vesiculation, it did not reach statistical significance. (c) Treatment with TG only resulted in a modest increase in
vesiculation in malignant MCF-7 cells compared to vehicle control. There were significant reductions in malignant cell vesiculation following
treatment with calpain inhibitor II (ALLM), TG + ALLM and TG + YM58483. Data represents the mean ± SD of at least 3 experiments. *p < 0.05,
**p < 0.005 ***p < 0.001 (one way ANOVA).
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cytoskeleton is destabilized, localized regions of the
membrane form membrane blebs and are released as
EVs. These are observed in morphological AFM studies
as uneven cellular surfaces with the presence of vesicle
derived pits (Figures 1–3).
Co-treatment of hCMEC-D3 cells with A23187 and
the intracellular Ca2+ chelator, BAPTA-AM, inhibited
vesiculation, again evidencing the essential role of Ca2+
mobilization in MV biogenesis (Figure 1(a)).
Interestingly, inhibiting calpain with ALLM in resting
hCMEC-D3 cells resulted in a modest increase in vesicu-
lation compared to untreated control (Figures 1(a), 4(b)).
Calpains are highly conserved cysteine proteases that,
when activated by Ca2+ cleave a number of substrates
including kinases and phosphatases, membrane recep-
tors, and cytoskeletal proteins and associated proteins
[68]. Some calpain substrates are responsible for alterna-
tive MV biogenesis pathways. For example, calpain
directly inhibits the small GTPase, RhoA that is an
upstream activator of ROCK1-mediated MV biogenesis
[21]. Thus, inhibition of this can activate the RhoA
mediated vesiculation pathway. Given chelation of intra-
cellular Ca2+ with BAPTA-AM prevents calpain activa-
tion, one would expect to see a similar rise in MV
production compared to treatment with ALLM.
However, treatment with BAPTA-AM completely blocks
vesiculation in resting non-malignant cells. This result
suggests the alternative plasma membrane EV biogenic
pathway may also be Ca2+ dependent.
Conversely, resting malignant cells produce signifi-
cantly more plasma membrane vesicles than their non-
malignant counterparts [20] (Figure 1). Our results
show that the higher resting level of vesiculation in
malignant cells is dependent on both intracellular cal-
cium and the activity of calpain as production can be
inhibited by both calcium modulators and the calpain
inhibitor ALLM (Figures 1 and 4). Resting malignant
cells display a surface topography consistent with
actively vesiculating cells: with an abundance of vesicle-
derived pits (Figure 1(b,c)). MCF-7 cells treated with
the calcium chelator, BAPTA-AM were devoid of vesi-
cle-derived pits and displayed a smooth surface mor-
phology (Figure 1(b,c)). Quantitative flow cytometry
verified these observations and demonstrated
a significant 1.4-fold reduction in vesiculation in
MCF-7 cells treated with ALLM (Figure 4(c)).
Quantitative analysis of surface topography with AFM
on fixed cells is somewhat cumbersome as image acqui-
sition is slow. This disadvantage makes this approach
unsuited to analysis of broader changes in vesiculation.
AFM is however, capable of resolving fine details in the
cellular surface such as vesicle-derived pits down to
100 nm in diameter. It is also important to note that
while analysis of surface roughness provides a measure
of topographical surface changes in different cells types
and treatment conditions, only the formation of plasma
membrane EV-derived pits has been correlated to pro-
duction of plasma membrane EVs previously.
These results evidence our proposal that resting
malignant cell plasma membrane EV biogenesis is
dependent on both Ca2+ and calpain and supports the
presence of discrete biogenic pathways in malignant
and non-malignant cells at rest [47].
A network of pumps, channels and exchangers
maintain tight regulatory control of intracellular Ca2+
homoeostasis [69]. This enables a multitude of signal-
ling modalities to be simultaneously operational in cells
[70]. Ca2+ is a highly promiscuous intracellular signal-
ling molecule and cellular effects are dependent on the
size, kinetics and subcellular localization of incoming
Ca2+ signals [71]. An increase in intracellular Ca2+ is
the initiating stimulus for both the collapse of mem-
brane phospholipid asymmetry, and for the activation
of calpain and cytoskeletal remodelling required for
plasma membrane EV biogenesis. What is intriguing
is the propensity of malignant cells to shed sponta-
neous EVs at rest. This is contrary to non-malignant
cells, which require cellular activation. The process in
malignant cells is Ca2+-dependent as chelation of intra-
cellular Ca2+ attenuates biogenesis (Figure 1). In adria-
mycin-resistant breast cancer cells, TRPC5 calcium
channels promote the formation of MVs [24]. While
this study demonstrated the importance of calcium
signalling in vesiculation, the differences in the bio-
genic pathways between malignant and non-
malignant cells were not examined.
The ER is the primary intracellular store of Ca2+,
which can be mobilized in response to numerous sti-
muli [61,72]. It provides the ideal starting point for the
interrogation of the specific Ca2+ signalling pathways
involved in plasma membrane EV biogenesis as it is
well documented to be involved in many cellular pro-
cesses. TG is commonly employed as an experimental
tool to interrogate Ca2+ signalling pathways and is has
high selectivity and potency as an irreversible inhibitor
of SERCA [73]. SERCA is responsible for the mainte-
nance of high Ca2+ concentration in the ER (≈100–-
800 µM) and its inhibition ultimately results in an
influx of Ca2+ into the cytosol. (Figure 5).
SERCA inhibitors such as TG are favoured in the Ca2+
signalling experimental toolkit, as direct depletion of Ca2+
from the ER bypasses other, interfering biochemical sig-
nals. As TG has also been employed in the study of
numerous cellular processes ranging from cytokine
release regulation in lymphocytes [74] to the dysregula-
tion of Ca2+ homoeostasis in cancer [40,54,71], it was
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chosen to interrogate Ca2+ signalling and plasma mem-
brane EV biogenesis in our cell lines. We demonstrate
that TG induces an increase in [Ca2+]i within 5 min in
MCF-7 cells (Figure 2(a,b)). As expected, pre-treatment
with BAPTA-AM inhibited TG-mediated [Ca2+]i
increases (Figure 2(a,b)). Importantly, corresponding to
Ca2+ increases, we observed a time-dependent change in
surfacemorphology in bothMCF-7 and hCMEC-D3 cells
indicative of an increase in vesiculation (Figure 2(c,d)).
Demonstrating for the first time that TG-mediated acti-
vation of SOCE can generate production of plasma mem-
brane EVs.
Having established TG as a suitable molecule for
activation of plasma membrane EV biogenesis and
a concentration that does not compromise cell viability
(Figure 3(b)), we interrogated the role of ER and SOCE
pathway in MV biogenesis.
We demonstrate that SOCE is involved in plasma
membrane EV biogenesis in both malignant MCF-7
and non-malignant hCMEC-D3 cells. Upon depletion
of intracellular stores of Ca2+ with TG, a significant
increase in vesicle biogenesis is observed in hCMEC-
D3 cells. While statistical significance was not reached
by flow cytometry, there is a consistent increase inMCF-
7 vesiculation observable in these and in our AFM
studies (Figures 1–2). Some malignant cells lines have
been reported to maintain higher basal Ca2+ concentra-
tions than normal cell lines [60], which could explain
why there is such a stark difference in vesiculation
before stimulation between hCMEC-D3 and MCF-7
cells. Roseblade et al. [20] proposed that higher basal
Ca2+ and activity of calpain contribute to higher levels of
basal vesiculation in malignant cells. Indeed, ALLM pre-
treatment of non-malignant cells reduced TG-mediated
vesicle production to levels comparable to control
(Figure 4(b)). In malignant cells, ALLM significantly
reduces TG-mediated vesiculation by 0.5 fold to levels
well below control (Figure 4(c)). This further supports
a calcium–calpain pathway driving malignant cell
plasma membrane vesiculation at rest and demonstrates
a role for SOCE in the pathway.
Dysregulation of Ca2+ homoeostasis and signalling is
complex and highly varied between cancer types [45].
Malignant cells often have remodelled Ca2+ signalling
pathways that provide them with a survival advantage
[43]. In the present study, differences between ER Ca2+
signalling pathways and, in particular, the SOCE path-
way in breast cancer cells was assessed in terms of plasma
membrane EV production with the selective SOCE inhi-
bitor, YM58483. The pyrazole analogue YM58483
Figure 5. Proposed model for the role of the endoplasmic reticulum and SOCE in MV biogenesis.
Malignant cells have high basal production of plasma membrane EVs compared to non-malignant cells which is driven by a calcium–calpain
dependent pathway. Resting vesiculation in MCF-7 cells is dependent on mobilization of calcium from stores within the endoplasmic reticulum
rather than from activity of plasma membrane channels. In the event of ER store-depletion – as observed when SERCA is inhibited with
thapsigargin – the store-operated calcium entry (SOCE) pathway is activated to restore ER calcium stores. Depleting ER calcium stores and
blocking the activity of Orai1 channels with a selective inhibitor of SOCE, YM58483, prevents intracellular calcium increases and inhibits the
production of EVs. Calcium signalling pathways are not activated in resting non-malignant hCMEC-D3 cells. Consequently, these cells are relatively
low vesiculators in the resting state. Following cellular activation (lightning bolt) or activation of SOCE with thapsigargin, there is an increase in
cytosolic calcium and activation of calpain. Calpain mediates remodelling of cytoskeletal proteins, disrupts anchorage of the plasma membrane to
the cytoskeleton and results in an increase in plasma membrane EV biogenesis.
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potently inhibits TG-mediated intracellular Ca2+
increases in non-excitable cells [67], effectively inhibits
SOCE in breast cancer cells [75], as well as inhibiting
T-cell activation mediated hypersensitivity reactions in
mice [76]. At rest, both malignant and non-malignant
vesiculation was unaffected when treated with YM58483
alone (Figure 4(a,b)). This demonstrates that basal vesi-
culation in both cell types is not dependent on SOCE–
hCMEC-D3 cells remain low vesiculators and MCF-7
cells remain high vesiculators.
We show that treatment of non-malignant hCMEC-D3
cells with YM58483 induced a significant reduction in TG-
promoted vesiculation compare to control (Figure 4(b)). In
this case, TG inhibits SERCA and results in Ca2+ depletion
from the ER, however SOCE is blocked and so less extra-
cellular Ca2+ enters cells. This renders the plasma mem-
brane EV biogenic machinery inactive and less vesicles are
released. These results demonstrate that SOCE is involved
in the biogenesis of plasma membrane EVs from both
MCF-7 and hCMEC-D3 cells. However, it appears that
SOCE acts as a secondary pathway of Ca2+ entry that is
activated down stream of ER store depletion. While this
does not completely explain differences in vesiculation at
rest betweenMCF-7 and hCMEC-D3 cells, it does demon-
strate differences in EV production between these malig-
nant and non-malignant cells could be related to altered
ER Ca2+ mobilization pathways (Figure 5). Importantly,
results reported here mainly focus on larger (≈1000 nm)
EV population only as particle analysis with flow cytome-
try is limited in the detection of particles below a few
hundred nanometres. This particle size detection limita-
tion prevents analysis on small EVs and therefore changes
in their production are not considered.
These results also provide interesting avenues for future
work. Malignant cells have higher basal Ca2+ activity and
some reports suggest this could be related to impaired
intracellular Ca2+ storage [77]. On the other hand, malig-
nant cells have also been reported to have increased expres-
sion and activity of ER Ca2+ channels – resulting in more
frequent mobilization from intracellular stores. In each
case, the ability of malignant cells to maintain high Ca2+
concentrations within intracellular Ca2+ store is impaired
and is therefore more susceptible to SERCA inhibition and
sensitive to store depletion. Future work aims to determine
if malignant cell vesiculation is vulnerable to store deple-
tion as this could prove to be useful in endeavours to
mitigate EV-mediated cancer progression with novel
therapeutics.
Conclusion
Cancer EVs are capable of transferring function proteins
and genetic material to recipient cells, bestowing upon
them a complex MDR phenotype [3,7,9,78,79]. In the
effort to develop novel strategies for the circumvention
of EV-mediated cancer progression, resistance and survi-
val it is imperative to understand the biogenic mechan-
isms that govern vesiculation. Here, we have
demonstrated that malignant MCF-7 cells are high vesi-
culators at rest compared to non-malignant hCMEC-D3
cells and this is dependent on Ca2+ mobilization and
activation of calpain.We found that the ER is the primary
source of Ca2+ for plasma membrane EV biogenesis and
that SOCE acts as a backup in the event of store depletion.
Further, we report that differences in malignant and non-
malignant vesiculation are related to altered mobilization
of Ca2+ from ER stores. Pharmacological manipulation of
ER Ca2+ stores has been a focus for many researchers
attempting target Ca2+ signalling in the treatment of
cancer. It now appears Ca2+ signalling may also be
a novel avenue to pursue in the effort to reduce EV-
mediated MDR and other deleterious cancer traits.
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